These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8854013)

  • 21. Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains.
    Abdelnabi R; Delang L; Neyts J
    Vaccine; 2017 Mar; 35(10):1370-1372. PubMed ID: 28189401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of the neurovirulence of poliovirus by non-radioisotope molecular analysis to quantify genomic changes.
    Horie H; Tano Y; Doi Y; Hashizume S
    Biologicals; 1998 Dec; 26(4):289-97. PubMed ID: 10403032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poliovirus vaccine strains in sewage and river water in South Africa.
    Pavlov DN
    Can J Microbiol; 2006 Aug; 52(8):717-23. PubMed ID: 16917529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees.
    Cuervo NS; Guillot S; Romanenkova N; Combiescu M; Aubert-Combiescu A; Seghier M; Caro V; Crainic R; Delpeyroux F
    J Virol; 2001 Jul; 75(13):5740-51. PubMed ID: 11390576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case for developing antiviral drugs against polio.
    Collett MS; Neyts J; Modlin JF
    Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat stability of the lyophilized Sabin poliovaccine.
    Shiomi H; Urasawa T; Urasawa S
    Jpn J Infect Dis; 2003 Apr; 56(2):70-2. PubMed ID: 12824691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The thermostability of vaccines. Technologies for improving the thermostability of the oral poliovirus vaccine.
    Lemon SM; Milstien JB
    Int J Technol Assess Health Care; 1994; 10(1):177-84. PubMed ID: 8157450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with vero cells at Pasteur Mérieux Connaught.
    Montagnon BJ; Vincent-Falquet JC; Saluzzo JF
    Dev Biol Stand; 1999; 98():137-40; discussion 167. PubMed ID: 10494966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between vaccine vial monitors and cold chain infrastructure in a rural district of India.
    Samant Y; Lanjewar H; Parker L; Block D; Stein B; Tomar G
    Rural Remote Health; 2007; 7(1):617. PubMed ID: 17288508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating vaccine derived polio viruses and their impact on global polio eradication.
    Wagner BG; Earn DJ
    Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
    Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
    Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
    Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
    Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania.
    Combiescu M; Guillot S; Persu A; Baicus A; Pitigoi D; Balanant J; Oprisan G; Crainic R; Delpeyroux F; Aubert-Combiescu A
    Arch Virol; 2007; 152(4):727-38. PubMed ID: 17195957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Water isotope effect on the thermostability of a polio viral RNA hairpin: A metadynamics study.
    Pathak AK; Bandyopadhyay T
    J Chem Phys; 2017 Apr; 146(16):165104. PubMed ID: 28456205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.